Perfuze

Executive Summary

Perfuze, an Irish medical device company founded in 2018, is developing the Millipede 088 aspiration catheter for acute ischemic stroke treatment. The device aims to improve clot removal efficiency and reduce procedural times, potentially offering superior clinical outcomes compared to current standard-of-care. As a pre-clinical stage company, Perfuze is focused on advancing its technology through necessary preclinical studies and regulatory pathways to enable first-in-human trials. The company is headquartered in Galway and operates within the cardiovascular and medical devices sectors. Despite limited public information, the innovative aspiration catheter design addresses a critical need in stroke intervention, a large and growing market driven by aging populations and increasing thrombectomy procedures. However, the company faces typical early-stage risks including technical validation, regulatory hurdles, and competition from established players. Success will depend on demonstrating safety and efficacy in preclinical models, securing financing, and initiating clinical studies. The Millipede 088 catheter's potential for faster and more complete revascularization could position Perfuze favorably if clinical data are positive.

Upcoming Catalysts (preview)

• TBDPreclinical study results60% success
• TBDFirst-in-human trial initiation30% success
• TBDSeries A or strategic partnership50% success